Physicians get a lot of email from pharma companies, and most of it looks the same: a product logo, a headline, a hero image, a block of copy, a button and a long tail of safety information. They have learned to recognize the shape before they read a word. When open rates fall, teams tend to blame the channel. The channel is fine. The email is the problem, and more specifically, the fact that it is the same email every physician got last month.
This guide is for brand, omnichannel and sales operations teams who run rep-triggered approved email, in Veeva or another CRM. It covers why HCP emails get ignored, how to plan a template library reps will actually use, how to write subject lines and bodies that stay compliant, what consent and fair balance require, and how to measure what matters.
What is approved email in pharma?
Approved email is the model most pharma companies use for emails sent by reps to healthcare professionals. Instead of writing their own messages, reps choose from templates that MLR has already approved, and personalize them only within fields the template allows, such as the physician's name, a greeting, or a choice between pre-approved content fragments. Veeva's Approved Email, available in Veeva CRM and Vault CRM, is the most widely used version, and other CRMs offer similar features.
The model exists because a rep email is promotion. Anything a rep writes about a product has to meet the same standards as a printed detail aid: consistent with the label, supported by evidence, balanced for risk. Free-form email from a rep's own account bypasses all of that, which is why most compliance policies forbid it. Approved email keeps the speed of email and the control of review.
The trade-off is that every variation has to be approved in advance. That is why template libraries tend to be small, generic and old. A rep with three approved emails sends one of three, to every physician, for months.
Why do HCPs ignore pharma emails?
Because most of them were not written for the physician who receives them. A template built to work for every prescriber in a therapy area will say the same thing to an academic specialist, a busy community practice and a physician who already prescribes the product. It answers none of their specific questions, so it gets the attention a generic message deserves.
Timing matters as much as content. The emails physicians value tend to follow something: a conversation with the rep, a question they asked, a sample request, a meeting they attended. The same content sent cold, as part of a blast cadence, reads as marketing. Sent the morning after a discussion about prior authorization, an access email is a useful follow-up.
And then there is the format. Many physicians read email on a phone, between patients. An email designed for a desktop, with key content inside an image that the email client has blocked, a long scroll to the point and a heavy safety block before anything useful, will not survive the first screen.
How to plan an approved email library reps will use
Plan by moment, not by message. List the situations in which a rep needs to follow up with a physician: after a first call, after an efficacy discussion, after a safety question, after an access or prior authorization question, after a sample request, before a speaker program, after a label update, and when a physician has gone quiet. Each moment needs at least one approved email, and the most common ones need versions by specialty.
Build from modules. A library of approved content blocks, such as an efficacy summary, an access block, a dosing block, each with its required safety information, lets you assemble many emails from claims MLR has already approved. Review then focuses on what is new in each template, rather than re-checking the same claim in twenty places.
Retire templates on a schedule. An approved email that has been in the library for a year may still be compliant, but physicians have seen it. Review usage and response data each quarter, retire what is not working, and replace it with variations on what is.
Writing subject lines and body copy that stay compliant
Keep claims out of the subject line and preview text. These are seen without the body of the email, so an efficacy claim there appears without the risk information that must accompany it. Use subject lines that say what the email is for, such as a follow-up to the rep's visit, the dosing information the physician asked for, or an update on coverage in their area. These are also the subject lines physicians are most likely to open.
Put the point in the first screen. One message per email, stated plainly at the top, with live text rather than an image so it shows even when images are blocked. If the email makes a benefit claim, the required safety information must be presented with comparable prominence, and the full prescribing information must be accessible, so plan the layout for that from the start rather than appending it at the end.
Make personalization real. A name in the greeting is not personalization. Choosing the right template for the physician's specialty, their questions and where they are in their relationship with the product is. Approved fragments that let a rep pick the paragraph that matches the conversation they just had do more for response than any subject line.
Consent, opt-out and safety information
The rules on consent depend on the market. In the US, commercial email to physicians generally needs a working opt-out, accurate sender information and a physical address, under the CAN-SPAM Act and company policy. In the EU and the UK, data protection and electronic marketing laws mean you usually need the physician's prior consent before sending promotional email at all. Most CRMs record consent per channel and per product, and reps should not be able to send to a physician without it.
Every promotional email needs its safety information and a route to the full prescribing information, presented to the standard of any other promotional material. A short email does not get a lighter standard. If an email genuinely cannot fit the required balance in a readable way, it is carrying too many claims.
Approved emails are promotional materials, and in the US are submitted to FDA on Form FDA 2253 at first use, like any other piece. Keep records of which version was sent to whom, so that if a template is withdrawn after a label change, you know who received it.
What to measure
Open rate is the least useful number, because privacy features in email clients inflate it and because an open does not mean the physician learned anything. Click-throughs to specific content, replies, requests for samples or a medical information response, and changes in the physician’s engagement with the rep are better measures.
Measure by template and by moment. Which follow-up after an access discussion leads to a reply? Which version for cardiologists gets clicks that the general version does not? Feed what you learn back into the library each quarter. Teams that do this end up with fewer templates that each work, instead of more templates that nobody sends.
Where SwishX fits
The reason most approved email libraries are small is the cost of making and reviewing each variation. Magic Studio writes Approved Email templates from the claims and dossiers your team has already approved, with versions by specialty and by moment, every claim cited to its source and checked against the label, and fair balance and safety information built into the layout as it is made.
Because every template is assembled from approved claims, review focuses on what is new, and finished templates go into your MLR queue and on into Veeva, rather than around it. Reps get an email for the conversation they just had, not the one everyone got last month.
Frequently asked questions
What is Veeva Approved Email?
Veeva Approved Email is a feature of Veeva CRM and Vault CRM that lets pharma reps send emails to healthcare professionals using templates and content fragments approved in advance by MLR review, with personalization limited to the fields each template allows.
Can pharma reps send their own emails to doctors?
Most company policies prohibit reps from sending free-form promotional emails, because anything a rep writes about a product is promotion and must be reviewed. Reps use approved email templates instead, and route off-label or medical questions to the medical information team.
Does a pharma email need fair balance?
Yes. A promotional email that makes a benefit claim must present risk information with comparable prominence and give access to the full prescribing information, to the same standard as other promotional material.
How can pharma companies improve HCP email open rates?
Send emails that follow a specific interaction, use subject lines that say plainly what the email contains rather than making claims, design for mobile with the key message in live text at the top, and maintain versions by specialty and situation rather than one generic template.
Do you need consent to email HCPs?
In the EU and UK, prior consent is usually required for promotional email to healthcare professionals. In the US, commercial email needs a working opt-out and accurate sender details, and company policies often add consent requirements. Your CRM should record consent by channel.